These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 27444986)

  • 21. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses.
    Boorjian SA; Crispen PL; Lohse CM; Leibovich BC; Blute ML
    Eur Urol; 2008 Oct; 54(4):855-63. PubMed ID: 18487007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Factors for Survival of Patients With Synchronous or Metachronous Brain Metastasis of Renal Cell Carcinoma.
    Choi SY; Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    Clin Genitourin Cancer; 2017 Dec; 15(6):717-723. PubMed ID: 28552571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analyses of Potential Predictive Markers and Response to Targeted Therapy in Patients with Advanced Clear-cell Renal Cell Carcinoma.
    Song Y; Huang J; Shan L; Zhang HT
    Chin Med J (Engl); 2015 Aug; 128(15):2026-33. PubMed ID: 26228213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases.
    Errarte P; Guarch R; Pulido R; Blanco L; Nunes-Xavier CE; Beitia M; Gil J; Angulo JC; López JI; Larrinaga G
    PLoS One; 2016; 11(12):e0169105. PubMed ID: 28033421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma.
    Patard JJ; Fergelot P; Karakiewicz PI; Klatte T; Trinh QD; Rioux-Leclercq N; Said JW; Belldegrun AS; Pantuck AJ
    Int J Cancer; 2008 Jul; 123(2):395-400. PubMed ID: 18464292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
    Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
    Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation of clear cell and non-clear cell renal cell carcinomas by all-relevant radiomics features from multiphase CT: a VHL mutation perspective.
    Li ZC; Zhai G; Zhang J; Wang Z; Liu G; Wu GY; Liang D; Zheng H
    Eur Radiol; 2019 Aug; 29(8):3996-4007. PubMed ID: 30523454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
    Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status and future directions of molecular markers in renal cell carcinoma.
    Rini BI
    Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.
    Kroeger N; Seligson DB; Klatte T; Rampersaud EN; Birkhäuser FD; Rao PN; Leppert JT; Zomorodian N; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    Eur Urol; 2012 May; 61(5):888-95. PubMed ID: 22269604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
    Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
    Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
    Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
    BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
    Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
    Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
    Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
    Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy.
    Kim HS; Kim WS; Park SH; Jung CW; Choi HY; Lee HM; Jeon SS; Ha H; Hwang IG; Lee S; Lim HY
    Urol Oncol; 2010; 28(2):157-63. PubMed ID: 18976937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.